Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],878.50,172791,DB01613,Erythrityl Tetranitrate
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],"1,994.04",172792,DB01613,Erythrityl Tetranitrate
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],314.82,172793,DB01613,Erythrityl Tetranitrate
,10024078,area under the time-concentration curve at 0 to 90 minutes AUC(0-90)],"Erythrityl tetranitrate (0.3 mg x kg(-1) oral [p.o.]) strikingly potentiated Hexarelin-stimulated GH secretion (31.25 microg x kg(-1) intravenous [i.v.]) in both young (area under the time-concentration curve at 0 to 90 minutes AUC(0-90)] 878.50 +/- 267.02 v 1,994.04 +/- 434.20 ng x mL(-1) x h, P < .01) and aged animals (314.82 +/- 117.11 v 1,314.12 +/- 484.75 ng x mL(-1) x h, P < .01).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],"1,314.12",172794,DB01613,Erythrityl Tetranitrate
,10024078,plasma,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],786.04,172795,DB01613,Erythrityl Tetranitrate
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],786.04,172796,DB01613,Erythrityl Tetranitrate
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],960.04,172797,DB01613,Erythrityl Tetranitrate
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],474.55,172798,DB01613,Erythrityl Tetranitrate
,10024078,peak,"Indomethacin (1.5 mg x kg(-1) i.m.) abolished the NO-donor potentiation of the GH response induced by Hexarelin in both young dogs (1,627.25 +/- 260.90 v 1,163.37 +/- 334.84 ng x mL(-1) x h, P < .05) and old dogs (1,061.47 +/- 210.38 v 365.69 +/- 79.27 ng x mL(-1) x h, P < .01) without affecting the plasma GH peak evoked by the peptide alone (young dogs, 786.04 +/- 153.44 v 960.04 +/- 444.44 ng x mL(-1) x h, P = NS; old dogs, 474.55 +/- 47.30 v 490.82 +/- 144.86 ng x mL(-1) x h, P = NS).",Nitric oxide modulation of the growth hormone-releasing activity of Hexarelin in young and old dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10024078/),[h·ng] / [ml],490.82,172799,DB01613,Erythrityl Tetranitrate
